CliffBio
biologic

Flucelvax, Flucelvax Quadrivalent

Influenza Vaccine

Loss of exclusivityMarch 2036projected — 12-year biologic exclusivity estimate
CompanySeqirus →View the full company profile on CliffBio

Drug detail

Brand nameFlucelvax, Flucelvax Quadrivalent
Active ingredientInfluenza Vaccine
Strength45UG/.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalMarch 2024
Marketing statusRx

More from Seqirus

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Flucelvax, Flucelvax Quadrivalent patent cliff — loss of exclusivity March 2036 | CliffBio